Xiaobo Bo

Xiaobo Bo


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 February 2022 in Frontiers in Oncology
Verified
Journal Article
Open access
LNLingxi Nan
Lingxi Nan
CWChangcheng Wang
Changcheng Wang
JWJie Wang
Jie Wang
SZShulong Zhang
Shulong Zhang
XBXiaobo Bo
Xiaobo Bo
HLHoubao Liu
Houbao Liu
Background: Recent studies have confirmed that AT-rich interactive domain-containing protein 1A (ARID1A) plays a critical role in tumorigenesis, but its role in gallbladder cancer (GBC) remains unclear.Methods: In total, 224 patients from Zhongshan Hospital were recruited for this retrospective study. The clinicopathological and baseline characteristics of the patients were collected. Bioinformatics analysis was performed to reveal variations in genes and signaling pathways, and ARID1A and PD-L1 expression and the number of PD1+ tumor-infiltrating lymphocytes (TILs) were measured by immunohistochemical staining.Results: ARID1A expression was negatively correlated with overall survival in patients with GBC, and multivariate analysis identified ARID1A as an independent prognostic factor for overall survival. A heatmap and gene set enrichment analysis suggested that cytotoxic T lymphocyte signatures and immune-related signaling pathways were downregulated in ARID1A low tumors. Subsequent immunohistochemical staining confirmed that ARID1A expression was negatively correlated with PD-L1 expression and PD1+ TILs in the tumor microenvironment. The Kaplan–Meier analysis suggested that high ARID1A expression combined with low PD-L1 expression or low PD1+ TIL counts is associated with the best prognosis in patients with GBC.Conclusion: ARID1A inactivation can lead to a worse prognosis in patients with GBC, potentially by mediating immune evasion through the PD1/PD-L1 pathway.

20 July 2026 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
CWChangcheng Wang
Changcheng Wang
LNLingxi Nan
Lingxi Nan
QMQingyang Meng
Qingyang Meng
CLChengjia Lu
Chengjia Lu
WCWenkai Cui
Wenkai Cui
XBXiaobo Bo
Xiaobo Bo
Introduction: The prognostic role of STMN1 and its regulatory effects on the tumor microenvironment (TME) in biliary tract cancer (BTC) remain poorly defined. This study aimed to investigate the prognostic value of STMN1 and its predictive capacity for chemotherapy and immunotherapy responses among patients with BTC. Methods: Six independent cohorts encompassing tissue microarray specimens and transcriptional profiling data from BTC patients were included in our analysis. STMN1 protein expression was quantified via immunohistochemistry (IHC) on tissue microarrays. Results: STMN1 expression was significantly correlated with inferior overall survival (OS). Multivariate regression further identified STMN1 as an independent adverse prognostic biomarker for OS. Gene Ontology (GO) and Gene Set Enrichment Analysis (GSEA) revealed that elevated STMN1 expression was tightly linked to immune response activation and T-cell infiltration, enabling the formation of an immune-inflamed TME in BTC. IHC validation confirmed positive correlations between STMN1 levels and anti-tumor CD8⁺ T-cell infiltration as well as programmed death-ligand 1 (PD-L1) expression. Patients with low STMN1 expression derived prominent survival benefits from gemcitabine-based adjuvant chemotherapy (ACT), whereas high STMN1 expression predicted superior therapeutic responses to immune checkpoint blockade (ICB) in BTC recipients. Discussion: STMN1 functions as an independent prognostic biomarker and differential predictive indicator for ACT and ICB efficacy in BTC, likely facilitating the construction of an immune-inflamed TME by promoting tumor immune cell recruitment and infiltration.

25 September 2023 in European Journal of Surgical Oncology
Verified
Journal Article
Open access
LNLingxi Nan
Lingxi Nan
CWChangcheng Wang
Changcheng Wang
JWJie Wang
Jie Wang
SXShijie Xu
Shijie Xu
XBXiaobo Bo
Xiaobo Bo
YWYueqi wang
Yueqi wang